CUE (Cue Biopharma) Cyclically Adjusted Revenue per Share: $6.12 (As of Mar. 2026)


CUE Cue Biopharma Inc CUE
63 GF Score
Price $36.78
GF Value $62.61
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cue Biopharma Cyclically Adjusted Revenue per Share?

Cue Biopharma CUE +0.74% 63 Cyclically Adjusted Revenue per Share is $6.12 as of Mar. 2026. GuruFocus rates CUE with a GF Score™ of 63/100 and a GF Value™ of $62.61 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cue Biopharma's adjusted revenue per share for the three months ended in Mar. 2026 was $1.183. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.12 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-11), Cue Biopharma's current stock price is $36.775. Cue Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $6.12. Cue Biopharma's Cyclically Adjusted PS Ratio of today is 6.01.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Cue Biopharma was 5.97. The lowest was 0.88. And the median was 4.01.


Cue Biopharma  (NAS:CUE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cue Biopharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.775/6.12
=6.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Cue Biopharma was 5.97. The lowest was 0.88. And the median was 4.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cue Biopharma Cyclically Adjusted Revenue per Share Related Terms


Cue Biopharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma Cyclically Adjusted Revenue per Share Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 6.12

CUE vs ALPS, AARD, KLRS: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Cue Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Cyclically Adjusted PS Ratio falls into.


CUE
63GF Score
Cue Biopharma Inc CUE
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cue Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.183/330.2130*330.2130
=1.183

Current CPI (Mar. 2026) = 330.2130.

Cue Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.000 236.525 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.256 251.989 0.335
201809 0.669 252.439 0.875
201812 0.492 251.233 0.647
201903 0.535 254.202 0.695
201906 1.520 256.143 1.960
201909 1.316 256.759 1.692
201912 1.303 256.974 1.674
202003 1.016 258.115 1.300
202006 1.142 257.797 1.463
202009 0.713 260.280 0.905
202012 0.470 260.474 0.596
202103 1.532 264.877 1.910
202106 2.631 271.696 3.198
202109 2.294 274.310 2.762
202112 7.750 278.802 9.179
202203 0.919 287.504 1.056
202206 0.022 296.311 0.025
202209 0.058 296.808 0.065
202212 0.116 296.797 0.129
202303 0.126 301.836 0.138
202306 0.926 305.109 1.002
202309 1.359 307.789 1.458
202312 1.158 306.746 1.247
202403 1.041 312.332 1.101
202406 1.590 314.175 1.671
202409 1.953 315.301 2.045
202412 0.635 315.605 0.664
202503 0.170 319.799 0.176
202506 0.928 322.561 0.950
202509 0.639 324.800 0.650
202512 6.088 324.054 6.204
202603 1.183 330.213 1.183

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $6.12 mean?
Cue Biopharma (CUE) has a Cyclically Adjusted Revenue per Share of $6.12 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cue Biopharma and its competitors.
Is Cue Biopharma's Cyclically Adjusted Revenue per Share too high?
Cue Biopharma's current Cyclically Adjusted Revenue per Share is $6.12. Overall, Cue Biopharma has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Cyclically Adjusted Revenue per Share compare to ALPS and AARD?
Cue Biopharma's Cyclically Adjusted Revenue per Share of $6.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current Cyclically Adjusted Revenue per Share is $6.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.61, compared to a current price of $36.78 — trading 41.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $6.12. Cue Biopharma's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Cyclically Adjusted Revenue per Share is $6.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (CUE) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of $36.78 is trading 41.3% below its estimated GF Value™ of $62.61. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for CUE:

  • Cyclically Adjusted Revenue per Share: $6.12
  • GF Value™: $62.61 vs. price of $36.78 (41.3% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cue Biopharma Business Description

Other Exchanges 1UC0:Germany
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
63GF Score

Get the complete analysis for CUE

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.78
Price
$62.61
GF Value